Short Communication
Volume 14:05, 2024

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Exploring the Role of Circulating Immune Cells in Kidney Disease Progression: Implications for Early Intervention

Maria Hernandez*

Department of Pediatric Nephrology, University of Barcelona, Barcelona, Spain

Introduction

Chronic Kidney Disease (CKD) is a global health crisis, with an increasing prevalence driven by factors such as hypertension, diabetes, and glomerulonephritis. One of the key mechanisms driving the progression of CKD is inflammation, particularly involving the immune system. While kidney injury is often seen as a localized event, emerging research has highlighted the pivotal role of circulating immune cells in driving renal inflammation and fibrosis [1]. These immune cells, including T cells, B cells, monocytes, and neutrophils, are recruited to the kidneys in response to injury and contribute to tissue damage through the release of pro-inflammatory cytokines and chemokines. Understanding the dynamic interactions between circulating immune cells and the kidney microenvironment is crucial for identifying novel biomarkers for early detection and developing targeted therapeutic interventions. This review explores the role of circulating immune cells in the pathogenesis of kidney disease, their contribution to disease progression, and how their modulation might offer new avenues for early intervention in CKD [2].

Description

Circulating immune cells and their role in kidney disease

The immune system plays a complex and multifaceted role in the pathogenesis of kidney disease. Circulating immune cells such as monocytes, T cells, B cells, and neutrophils are key players in the kidney's inflammatory response to injury. Under normal conditions, the kidney maintains an immunologically privileged status, but when the organ is injured due to factors like infection, ischemia, or hypertension immune cells are rapidly mobilized to the site of damage. Monocytes and macrophages are among the first immune cells to infiltrate the kidney. They are involved in both acute inflammation and tissue repair but can also drive chronic inflammation and fibrosis when their activation is unchecked. These cells can polarize into M1 macrophages, which exacerbate inflammation and tissue injury, or M2 macrophages, which promote tissue repair. Similarly, T cells, particularly CD4+ T helper cells and CD8+ cytotoxic T cells, are activated during kidney injury and contribute to the progression of kidney disease by secreting inflammatory cytokines and recruiting additional immune cells to the renal tissue. Neutrophils, another type of circulating immune cell, play a crucial role in the early stages of kidney injury by responding to damage signals and releasing pro-inflammatory molecules. However, excessive neutrophil recruitment and activation contribute to tissue damage and fibrosis in the long term [3].

Immune cell recruitment and tissue injury

The recruitment of immune cells to the kidney is mediated by chemokines and cytokines that are produced in response to injury. For example, monocyte Chemoattractant Protein-1 (MCP-1) and C-C Chemokine Receptor type 2 (CCR2) are upregulated in response to kidney injury and play a crucial role in the recruitment of monocytes to the kidneys. Once in the kidney, these cells differentiate into macrophages and, depending on the signals they receive from the kidney microenvironment, can contribute to either repair or ongoing damage. T cells, especially Th17 cells, have also been implicated in the pathogenesis of CKD through their production of pro-inflammatory cytokines such as IL-17, which promotes endothelial dysfunction, tissue injury, and fibrosis. [4] In diseases such as lupus nephritis and glomerulonephritis, circulating immune cells play an even more pronounced role in the progression of renal disease, as the immune system incorrectly targets kidney tissue, leading to inflammation and organ damage [4].

Implications for early intervention and therapeutic strategies

Given the central role of circulating immune cells in the progression of kidney disease, targeting these cells offers potential strategies for early intervention and disease-modifying therapies. Several approaches are currently being investigated:

Targeting inflammatory pathways: The use of immune modulators or biologic therapies that target key inflammatory cytokines, such as TNF-αIL-6, or IL-17, may help reduce the systemic and local immune response in the kidney. For instance, IL-6 inhibitors have shown promise in reducing inflammation and improving kidney function in preclinical models of CKD. TNF-αinhibitors, already used in autoimmune diseases, have also demonstrated potential in treating CKD by modulating immune cell function and reducing inflammation.

Selective immune cell depletion: Targeting specific subsets of immune cells that contribute to kidney damage, such as macrophages or T cells, is another promising therapeutic strategy. Monocyte depletion or the inhibition of monocyte migration to the kidney has been shown to reduce inflammation and prevent the progression of kidney fibrosis in animal models. Similarly, depleting CD4+ T cells or Th17 cells may reduce kidney injury and fibrosis, particularly in autoimmune-mediated kidney diseases.

Immune checkpoint inhibitors: Recent advances in cancer immunotherapy have led to the exploration of immune checkpoint inhibitors as potential treatments for kidney diseases. PD-1/PD-L1 inhibitors, which block the immune checkpoint pathway, have shown efficacy in treating various cancers and may also help modulate the immune response in kidney disease, promoting tissue repair rather than damage.

Cell-based therapies: Regulatory T cells (Tregs), which suppress immune responses and promote tissue repair, are being investigated for their potential to modulate immune responses in CKD. Treg cell therapy may be particularly useful in preventing fibrosis and promoting kidney regeneration by dampening excessive immune activation and inflammation.

Biomarkers for early detection: Immune cells and their associated cytokines and chemokines can serve as biomarkers for early detection and monitoring of kidney disease progression. Profiling the immune cell populations in the blood, urine, or kidney biopsy samples may help identify patients at risk for rapid progression of CKD and guide early therapeutic interventions [5].

Conclusion

Circulating immune cells play a critical role in the progression of kidney disease by mediating inflammatory responses, recruiting additional immune cells, and contributing to fibrosis. Their involvement in both acute and chronic

***Address for Correspondence:** Maria Hernandez, Department of Pediatric Nephrology, University of Barcelona, Barcelona, Spain; E-mail: maria.hernandez@ub.edu*

Received: 02 September, 2024, Manuscript No. jnt-24-155664; **Editor Assigned:** 04 September, 2024, PreQC No. P-155664; **Reviewed:** 16 September, 2024, QC No. Q-155664; **Revised:** 23 September, 2024, Manuscript No. R-155664; **Published:** 30 September, 2024, DOI: 10.37421/2161-0959.2024.14.525

phases of kidney injury highlights their potential as both biomarkers for early detection and targets for therapeutic intervention. Modulating the activity of specific immune cell subsets, inhibiting key inflammatory pathways, and utilizing immune cell-based therapies hold promise for slowing or even reversing kidney damage in CKD patients. As our understanding of the immune system's role in kidney disease deepens, targeted therapies that specifically address immune cell activation and recruitment may provide novel opportunities for early intervention and personalized treatment of CKD, ultimately improving patient outcomes and reducing the burden of kidney disease worldwide. Ongoing research will be crucial in determining the most effective and safe approaches for harnessing the immune system to treat kidney diseases.

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Alonso-Galicia, Magdalena, Michael W. Brands, Dion H. Zappe and John E. Hall. "Hypertension in obese Zucker rats: Role of angiotensin II and adrenergic activity." *Hypertension* (1996): 1047-1054.
2. Mallamaci, Francesca, Piero Ruggenenti, Annalisa Perna and Daniela Leonardis et al. "ACE inhibition is renoprotective among obese patients with proteinuria." *J Am Soc Nephrol* (2011): 1122-1128.
3. Spoto, Belinda, Anna Pisano and Carmine Zoccali. "Insulin resistance in chronic kidney disease: A systematic review." *Am J Physiol Renal Physiol* (2016): F1087-F1108.
4. Raj, Desh, Bhawna Tomar, Amit Lahiri and Shrikant R. Mulay. "The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease." *Pharmacol Res* (2020): 104617.
5. Jiang, Zongmiao, Yao Wang, Xue Zhao and Haiying Cui et al. "Obesity and chronic kidney disease." *Am J Physiol Endocrinol Metab* (2023): E24-E41.

How to cite this article: Hernandez, Maria. "Exploring the Role of Circulating Immune Cells in Kidney Disease Progression: Implications for Early Intervention." *J Nephrol Ther* 14 (2024): 525.